Incidence and Mortality Associated with Cardiovascular Medication among Hypertensive COVID-19 Patients in South Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: We aimed to investigate whether the use of cardiovascular drugs in coronavirus disease 2019 (COVID-19) patients withhypertension as a comorbidity has a significant effect on the incidence and associated mortality rate of COVID-19. Materials and Methods: Data covering the period between January 1, 2020 and June 4, 2020 were extracted from The NationalHealth Insurance Service-COVID-19 (NHIS-COVID-19) database in South Korea and analyzed as a population-based cohort study. Results: A total of 101657 hypertensive adults aged 20 years or older were included for final analysis. Among them, 1889 patients(1.9%) were diagnosed with COVID-19 between January 1, 2020 and June 4, 2020, and hospital mortality occurred in 193 patients(10.2%). In a multivariable model, the use of beta-blockers was associated with an 18% lower incidence of COVID-19 [odds ratio(OR): 0.82, 95% confidence interval (CI): 0.69–0.98; p=0.029]. Among 1889 hypertensive patients diagnosed with COVID-19, theuse of a calcium channel blocker (CCB) was associated with a 42% lower hospital mortality rate (OR: 0.58, 95% CI: 0.38–0.89;p=0.012). The use of other cardiovascular drugs was not associated with the incidence of COVID-19 or hospital mortality rateamong COVID-19 patients. Similar results were observed in all 328374 adults in the NHIS-COVID-19 database, irrespective of thepresence of hypertension. Conclusion: In South Korea, beta-blockers exhibited potential benefits in lowering the incidence of COVID-19 among hypertensivepatients. Furthermore, CCBs may lower the hospital mortality rate among hypertensive COVID-19 patients. These findingswere also applied to the general adult population, regardless of hypertension
Abstract
Purpose: We aimed to investigate whether the use of cardiovascular drugs in coronavirus disease 2019 (COVID-19) patients withhypertension as a comorbidity has a significant effect on the incidence and associated mortality rate of COVID-19. Materials and Methods: Data covering the period between January 1, 2020 and June 4, 2020 were extracted from The NationalHealth Insurance Service-COVID-19 (NHIS-COVID-19) database in South Korea and analyzed as a population-based cohort study. Results: A total of 101657 hypertensive adults aged 20 years or older were included for final analysis. Among them, 1889 patients(1.9%) were diagnosed with COVID-19 between January 1, 2020 and June 4, 2020, and hospital mortality occurred in 193 patients(10.2%). In a multivariable model, the use of beta-blockers was associated with an 18% lower incidence of COVID-19 [odds ratio(OR): 0.82, 95% confidence interval (CI): 0.69–0.98; p=0.029]. Among 1889 hypertensive patients diagnosed with COVID-19, theuse of a calcium channel blocker (CCB) was associated with a 42% lower hospital mortality rate (OR: 0.58, 95% CI: 0.38–0.89;p=0.012). The use of other cardiovascular drugs was not associated with the incidence of COVID-19 or hospital mortality rateamong COVID-19 patients. Similar results were observed in all 328374 adults in the NHIS-COVID-19 database, irrespective of thepresence of hypertension. Conclusion: In South Korea, beta-blockers exhibited potential benefits in lowering the incidence of COVID-19 among hypertensivepatients. Furthermore, CCBs may lower the hospital mortality rate among hypertensive COVID-19 patients. These findingswere also applied to the general adult population, regardless of hypertension
참고문헌 (33)
- Bedford J, "COVID-19 : towards controlling of a pandemic", Lancet, 395, pp.1015~1018 (2020)
- "Coronavirus Resource Center. Global map of cases and deaths by country/region/sovereignty"[URL]
- Dagan N, "BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting", N Engl J Med, 384, pp.1412~1423 (2021)
- Knoll MD, "Oxford-AstraZeneca COVID-19 vaccine efficacy", Lancet, 397, pp.72~74 (2021)
- Fontanet A, "COVID-19 herd immunity: where are we?", Nat Rev Immunol, 20, pp.583~584 (2020)
- Schiffrin EL, "Hypertension and COVID-19", Am J Hypertens, 33, pp.373~374 (2020)
- Zhou F, "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study", Lancet, 395, pp.1054~1062 (2020)
- Gao C, "Association of hypertension and antihypertensive treatment with COVID-19mortality : a retrospective observational study", Eur Heart J, 41, pp.2058~2066 (2020)
- Drager LF, "Is hypertension a real risk factor for poor prognosis in the COVID-19 pandemic?", Curr Hypertens Rep, 22, pp.43~ (2020)
- Kreutz R, "Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury : implications for COVID-19", Cardiovasc Res, 116, pp.1688~1699 (2020)
- Rico-Mesa JS, "Outcomes in patients with COVID-19 infection taking ACEI", ARB, 2020, pp.22, 31~
- South AM, "COVID-19, ACE2, and the cardiovascular consequences", Am J Physiol Heart Circ Physiol, 318, pp.H1084~90 (2020)
- Kuster GM, "SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?", Eur Heart J, 41, pp.1801~1803 (2020)
- "Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients" (2020)[URL]
- Devaux CA, "ACE2 receptor polymorphism : susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome", J Microbiol Immunol Infect, 53, pp.425~435 (2020)
- Yang G, "Effects of angiotensin II receptor blockers and ACE(angiotensin-converting enzyme)inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension : a single-center retrospective study", Hypertension, 76, pp.51~58 (2020)
- Zhang P, "Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19", Circ Res, 126, pp.1671~1681 (2020)
- Zhang LK, "Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension", Cell Discov, 6, pp.96~ (2020)
- Vasanthakumar N, "Can beta-adrenergic blockers be used in the treatment of COVID-19?", Med Hypotheses, 142, pp.109809~ (2020)
- von Elm E, "The Strengthening the Reporting of Observational Studies in Epidemiology(STROBE)Statement : guidelines for reporting observational studies", Int J Surg, 12, pp.1495~1499 (2014)
- Vasanthakumar Natesan, "SARS-CoV-2 host cell entry might involve Beta adrenergic receptors", OSF Preprints (2020), Center for Open Science[DOI]
- Tan K, "The association between premorbid beta blocker exposure and mortality in sepsis-a systematic review", Crit Care, 23, pp.298~ (2019)
- Noveanu M, "Effect of oral β-blocker on short and long-term mortality in patients with acute respiratory failure : results from the BASELII-ICU study", Crit Care, 14, pp.R198~ (2010)
- Emma Rezel‐Potts, "Antihypertensive medications and COVID‐19 diagnosis and mortality: Population‐based case‐control analysis in the United Kingdom", British Journal of Clinical Pharmacology, 87(12), pp.4598~4607 (2021), Wiley[DOI]
- Lai AL, "The SARS-CoV fusion peptide forms an extended bipartite fusion platform that perturbs membrane order in a calcium-dependent manner", J Mol Biol, 429, pp.3875~3892 (2017)
- Marco R. Straus, "Inhibitors of L-type calcium channels show therapeutic potential for treating SARS-CoV-2 infections by preventing virus entry and spread", bioRxiv, ~ (2020)
- Sardu C, "Could anti-hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID-19 infection? Data from centers of Southern Italy", J Am Heart Assoc, 9, pp.e016948~ (2020)
- Antithrombotic Trialists’(ATT)Collaboration, "Aspirin in the primary and secondary prevention of vascular disease : collaborative meta-analysis of individual participant data from randomised trials", Lancet, 373, pp.1849~1860 (2009)
- Alegbeleye BJ, "The novel aspirin as breakthrough drug for COVID-19 : a narrative review", Iberoam J, 2, pp.335~350 (2020)
- Mehta P, "COVID-19 : consider cytokine storm syndromes and immunosuppression", Lancet, 395, pp.1033~1034 (2020)
- Chen T, "Clinical characteristics of 113 deceased patients with coronavirus disease 2019:retrospective study", BMJ, pp.m1091~ (2020)
- Giannis D, "Coagulation disorders in coronavirus infected patients : COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past", J Clin Virol, 127, pp.104362~ (2020)
- Bianconi V, "Is acetylsalicylic acid a safe and potentially useful choice for adult patients with COVID-19?", Drugs, 80, pp.1383~1396 (2020)